Celera Genomics Signs Five Academic Institutions to the Celera Discovery System.

Business Editors and Health/Medical Writers

BIOWIRE2K

ROCKVILLE, Md.--(BW HealthWire)--July 19, 2001

Celera Also Signs Three Additional Centers to

Existing UT Southwestern Subscription

Celera Genomics (NYSE:CRA), an Applera Corporation business, announced today it signed multi-year agreements with University of Alabama at Birmingham, Case Western Reserve University School of Medicine, Fred Hutchinson Cancer Research Center, University of Oxford in England, and Pennington Biomedical Research Center at Louisiana State University, which allows these investigators access to Celera's database products. The subscribers will access Celera's database information and research tools through its Celera Discovery System(TM).

The University of Texas Health Science Centers at Houston and San Antonio, and the University of Texas Medical Branch now also have access to the Celera databases as part of the existing University of Texas Southwestern Medical Center at Dallas subscription deal signed with Celera in July 2000. Financial terms of the agreements were not disclosed.

The Celera Discovery System is an integrated, web-based platform that enables users to leverage Celera's computational tools, super-computing power, and the genomic and biological data to advance the discovery process for researchers worldwide.

About Celera

Applera Corporation comprises two operating groups. The Celera Genomics Group, an integrated source of genomic and related medical information headquartered in Rockville, Md., is evolving to become a next generation diagnostic and therapeutic discovery company. Celera intends to leverage its industrialized approach to biology to develop platforms for enabling these new discoveries both for its own internal product development and for its customers, including collaboration partners and subscribers. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, Calif., and reported sales of $1.4 billion during fiscal 2000. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800/762-6923.

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "anticipate," and "potential," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in forward-looking statements within this press release. The risks and uncertainties include but are not limited to: (1) dependence on the continued assembly and annotation of the human and mouse genomes; (2) unproven use of genomics information to develop products; (3) dependence on computer hardware, software, and internet applications; (4) potential adverse effect on the Celera Genomics group's intellectual property protection and the value of its products and services due to public disclosure of genomics sequence data; (5) government regulation of Celera's products and services; and (6) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission.

Note to Editors: Applera, Celera, Celera Genomics, and Celera Discovery System are trademarks and Applied Biosystems is a registered trademark of Applera Corporation or its subsidiaries in the US and certain other countries.